Tenax Therapeutics (TENX) has released an update.
Tenax Therapeutics, Inc. has announced a significant milestone with the US Patent and Trademark Office granting a patent for their levosimendan variants, including oral, subcutaneous, and intravenous forms, and its active metabolites. This patent protects the use of these drugs, alone or in combination with other cardiovascular medications, to enhance exercise performance in patients with pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF), marking a potential breakthrough in the treatment of this condition.
For further insights into TENX stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
